Investigators will evaluate whether low-dose methotrexate will reduce rates of myocardial infarction, stroke, or cardiovascular death among patients with a recent history of coronary artery disease and either type II diabetes or metabolic syndrome.
Contact Anne McDonald, RN or Kathleen Allain, LPN at 508-368-3929 for more information.
For more information about this study:
https://clinicaltrials.gov/ct2/show/NCT01594333
